Celgene (CELG) Wins FDA Approval for Pomalyst in Multiple Myeloma

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/24/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. BABA
7. AVGO
8. SPCX
9. NTES
10. DE

February 8, 2013 3:31 PM EST

Price: $108.24 --0%

Overall Analyst Rating:
SELL (= Flat)

Celgene Corp (NASDAQ: CELG) is said to have won FDA approval for pomalidomide in multiple myeloma.

FDA, Insiders' Blog

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!